Merck's Welireg Fails to Achieve Primary Endpoint in Phase 3 Trial as First-Line Treatment for Renal Cell Carcinoma
Merck & Co. (MRK) and Eisai (ESALY) have jointly developed Welireg (belzutifan), a HIF-2α inhibitor, which has unexpectedly failed in the Phase 3 LITESPARK-012 trial. The trial evaluated the efficacy of a triple combination therapy of Welireg, Keytruda, and Lenvima as a first-line treatment for advanced clear cell Renal Cell Carcinoma (ccRCC). However, the combination therapy did not significantly improve Progression-Free Survival (PFS) or Overall Survival (OS). Given the drug's strong performance in previous late-stage and adjuvant trials, this failure in the first-line treatment setting, the largest market, has significantly impacted the industry and investors.
The triple combination therapy, which also included Merck's anti-CTLA-4 antibody quavonlimab, failed to demonstrate superiority compared to the control group. This highlights the challenges of simply adding a new mechanism of action to existing Immune Checkpoint Inhibitor and VEGF-targeted therapy combinations to achieve synergistic effects. The medical community has now confirmed how difficult it is to achieve additional clinical benefits without increasing toxicity when building upon the already established and potent standard treatment of Keytruda plus Lenvima.
This clinical failure represents a significant setback for Merck's long-term strategy to diversify its portfolio and strengthen its market position in the renal cell carcinoma field, aiming to reduce its reliance on Keytruda, which is facing patent expiration. The market had initially projected Welireg's annual peak sales to be approximately USD $2.6 billion, a figure based on its entry into the first-line treatment market, and this forecast will likely be revised. Fortunately, Welireg's annual revenue in 2025 increased by 41% year-over-year to USD $716 million, and it has been steadily expanding its indications since its initial FDA approval in August 2021.
Despite this failure in the first-line setting, Welireg is awaiting the FDA's decision on its approval for second-line treatment in patients with prior treatment history, with a PDUFA date of October 4, 2026 (based on the LITESPARK-011 results). Merck is also actively pursuing market defense through collaborations with Exelixis, continuing trials such as the LITESPARK-033 trial with zanzalintinib. However, Arcus Biosciences, a competitor, is rapidly developing casdatifan, a competing HIF-2α inhibitor, making the future technology competition one to watch.
This LITESPARK-012 Phase 3 trial failure will hinder Merck & Co. (MRK)'s long-term growth strategy by preventing Welireg (belzutifan) from entering the first-line treatment market in the global renal cell carcinoma (RCC) market, which is valued at USD $7.3 billion in 2025. For oncologists, this case underscores the necessity of more precise biomarker-driven patient selection strategies beyond simple combination therapies to overcome the strong therapeutic barrier of existing standard treatments, such as Keytruda (pembrolizumab) and Lenvima (lenvatinib). Competitors such as Arcus Biosciences (RCUS), developing casdatifan and other HIF-2α inhibitor pipeline assets, will have the opportunity to learn from Merck's failure and differentiate themselves through toxicity control and targeted patient populations. While achieving the previously expected peak sales of USD $2.6 billion for Welireg will be challenging, Merck's mid-term market share will depend on the outcome of the PDUFA date of October 4, 2026, for the approval of second-line treatment in patients with prior VEGF treatment history, and the results of subsequent Phase 3 trials with Exelixis and others.